Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention.
Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention.
复制标题
DOI：
10.1007/s11606-022-07891-w
复制
发表时间：
2023-03
影响因子：
5.7
通讯作者：
Dick, Andrew W.
中科院分区：
文献类型：
--
作者：
Stein, Bradley D.;Landis, Rachel K.;Sheng, Flora;Saloner, Brendan;Gordon, Adam J.;Sorbero, Mark;Dick, Andrew W.
在新冠病毒大流行期间，尽管一些研究表明开始使用丁丙诺啡的患者有所减少，但总体丁丙诺啡治疗似乎保持相对稳定。关于大流行期间丁丙诺啡治疗模式的经验信息很少。为了更好地了解大流行期间丁丙诺啡发作的模式以及这些模式与大流行前的模式相比如何。药房索赔约占美国所有 50 个州和哥伦比亚特区零售药房处方药的 92%。填写用于治疗阿片类药物使用障碍的丁丙诺啡处方的个人。 2020年3月13日至12月1日的活跃、开始和结束丁丙诺啡治疗次数，以及基于2019年3月13日至12月1日治疗次数增长的2020年预期此类发作次数。2020年12月观察到的活跃丁丙诺啡发作次数与预期数量相当，但3月13日至12月1日之间开始的新治疗次数， 2020 年，比 2019 年的预期减少 17.2% 经验。同样，2020 年 3 月 13 日至 12 月 1 日期间结束的剧集数量比预期少 16.0%。在此期间，事件开始和结束的预期数量均有所下降，但在宣布公共卫生紧急状态后的两个月内下降幅度最大。在大流行期间丁丙诺啡患者数量表面上稳定的背后，接受丁丙诺啡治疗的人数发生了巨大变化。我们的研究结果揭示了支持丁丙诺啡处方的政策变化如何影响该时期的处方动态，这表明虽然政策努力可能成功地维持了现有患者的治疗，但这种成功并没有延伸到尚未接受治疗的个人。
During the COVID pandemic, overall buprenorphine treatment appeared to remain relatively stable, despite some studies suggesting a decrease in patients starting buprenorphine. There is a paucity of empirical information regarding patterns of buprenorphine treatment during the pandemic. To better understand the patterns of buprenorphine episodes during the pandemic and how those patterns compared to pre-pandemic patterns. Pharmacy claims representing approximately 92% of all prescriptions filled at retail pharmacies in all 50 US states and the District of Columbia. Individuals filling buprenorphine prescriptions indicated for treatment of opioid use disorder. The number of active, starting, and ending buprenorphine treatment episodes March 13 to December 1, 2020, and the expected number of such episodes in 2020 based on the growth in treatment episodes from March 13 to December 1, 2019. The observed number of active buprenorphine episodes in December 2020 was comparable to the expected number, but new treatment episodes starting between March 13 and December 1, 2020, were 17.2% fewer than expected based on the 2019 experience. Similarly, the number of episodes that ended between March 13 and December 1, 2020, was 16.0% fewer than expected. Decreases from expected episode starts and ends occurred throughout the period but were greatest in the 2 months after the declaration of the public health emergency. Beneath the apparent stability of buprenorphine patient numbers during the pandemic, the flow of individuals receiving buprenorphine treatment changed substantially. Our findings shed light on how policy changes meant to support buprenorphine prescribing influenced prescribing dynamics during that period, suggesting that while policy efforts may have been successful in maintaining existing patients in treatment, that success did not extend to individuals not yet in treatment.
登录
查看更多内容
影响因子：
5.7
作者：
Samuels EA;Khatri UG;Snyder H;Wightman RS;Tofighi B;Krawczyk N
通讯作者：
Krawczyk N
影响因子：
3.9
作者：
Cantor J;Dick AW;Haffajee R;Pera MF;Bravata DM;Stein BD;Whaley CM
通讯作者：
Whaley CM
DOI：
10.1001/jamahealthforum.2021.3833
发表时间：
2021-11
期刊：
JAMA HEALTH FORUM
影响因子：
--
作者：
Pessar, Seema Choksy;Boustead, Anne;Ge, Yimin;Smart, Rosanna;Pacula, Rosalie Liccardo
通讯作者：
Pacula, Rosalie Liccardo
影响因子：
2.1
作者：
Yee CA;Legler A;Davies M;Prentice J;Pizer S
通讯作者：
Pizer S
DOI：
10.1080/00952990.2021.1903023
发表时间：
2021-07-04
期刊：
The American journal of drug and alcohol abuse
影响因子：
--
作者：
Andraka-Christou B;Bouskill K;Haffajee RL;Randall-Kosich O;Golan M;Totaram R;Gordon AJ;Stein BD
通讯作者：
Stein BD